Price Alert

Autolus Therapeutics (AUTL)

NASDAQ: AUTL · Real-Time Price · USD

1.73

-0.12 (-6.49%)

At close: Aug 15, 2025, 3:59 PM

1.76

1.73%

After-hours: Aug 15, 2025, 07:55 PM EDT

Autolus Therapeutics Statistics

Share Statistics

Autolus Therapeutics has 266.14M shares outstanding. The number of shares has increased by 0.03% in one year.

Shares Outstanding	266.14M
Shares Change (YoY)	0.03%
Shares Change (QoQ)	0%
Owned by Institutions (%)	56.88%
Shares Floating	240.33M
Failed to Deliver (FTD) Shares	15,004
FTD / Avg. Volume	0.76%

Short Selling Information

The latest short interest is 13.66M, so 5.13% of the outstanding shares have been sold short.

Short Interest	13.66M
Short % of Shares Out	5.13%
Short % of Float	6.76%
Short Ratio (days to cover)	9.36

Valuation Ratios

The PE ratio is -2.72 and the forward PE ratio is -3.24. Autolus Therapeutics's PEG ratio is 0.1.

PE Ratio	-2.72
Forward PE	-3.24
PS Ratio	59.25
Forward PS	5
PB Ratio	1.4
P/FCF Ratio	-2.49
PEG Ratio	0.1

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Autolus Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.88, with a Debt / Equity ratio of 0.12.

Current Ratio	10.88
Quick Ratio	10.81
Debt / Equity	0.12
Debt / EBITDA	-0.29
Debt / FCF	-0.22
Interest Coverage	-25.98

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$15.64K
Profits Per Employee	$-341.05K
Employee Count	647
Asset Turnover	0.01
Inventory Turnover	2.75

Taxes

Income Tax	1.53M
Effective Tax Rate	-0.7%

Stock Price Statistics

The stock price has increased by -33.15% in the last 52 weeks. The beta is 1.9, so Autolus Therapeutics's price volatility has been higher than the market average.

Beta	1.9
52-Week Price Change	-33.15%
50-Day Moving Average	2.31
200-Day Moving Average	2.25
Relative Strength Index (RSI)	46.75
Average Volume (20 Days)	1,985,872

Income Statement

In the last 12 months, Autolus Therapeutics had revenue of 10.12M and earned -220.66M in profits. Earnings per share was -0.86.

Revenue	10.12M
Gross Profit	-1.27M
Operating Income	-241.43M
Net Income	-220.66M
EBITDA	-182.42M
EBIT	-209.84M
Earnings Per Share (EPS)	-0.86

Full Income Statement

Balance Sheet

The company has 227.38M in cash and 52.63M in debt, giving a net cash position of 174.75M.

Cash & Cash Equivalents	227.38M
Total Debt	52.63M
Net Cash	174.75M
Retained Earnings	-1.1B
Total Assets	746.34M
Working Capital	549.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -206.27M and capital expenditures -34.82M, giving a free cash flow of -241.09M.

Operating Cash Flow	-206.27M
Capital Expenditures	-34.82M
Free Cash Flow	-241.09M
FCF Per Share	-0.94

Full Cash Flow Statement

Margins

Gross margin is -12.52%, with operating and profit margins of -2385.63% and -2180.45%.

Gross Margin	-12.52%
Operating Margin	-2385.63%
Pretax Margin	-2165.36%
Profit Margin	-2180.45%
EBITDA Margin	-1802.61%
EBIT Margin	-2385.63%
FCF Margin	-2382.31%

Dividends & Yields

AUTL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AUTL is $10, which is 306.5% higher than the current price. The consensus rating is "Buy".

Price Target	$10
Price Target Difference	306.5%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-1.39
Piotroski F-Score	1